MINI FUTURE LONG - ASTRAZENECA | Delayed Deutsche Boerse AG 11:21:08 2024-07-11 am EDT | ||
| 4.56 EUR | +0.66% |
|
| Current month | -8.11% | ||
| 1 month | -13.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 4.56 | +0.66% |
| 24-07-10 | 4.53 | +2.95% |
| 24-07-09 | 4.4 | -2.00% |
| 24-07-08 | 4.49 | +0.22% |
| 24-07-05 | 4.48 | -3.03% |
Delayed Quote Deutsche Boerse AG
Last update July 11, 2024 at 11:21 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PD5KK4 |
| ISIN | DE000PD5KK48 |
| Date issued | 2022-05-05 |
| Strike | 8,251 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.77 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.35 € |
|---|---|
| Lowest since issue | 1.68 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
155.1
USD
Average target price
175.5
USD
Spread / Average Target
+13.14%
- Stock Market
- Certificates
- Certificat
